Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Celgene_Corporation
|
| gptkbp:acquired |
gptkb:Celgene_Corporation
|
| gptkbp:focus |
development of therapies for hematologic diseases
|
| gptkbp:founded |
gptkb:2015
|
| gptkbp:founder |
gptkb:Dr._John_D._Mc_Carty
|
| gptkbp:headquarters |
gptkb:San_Diego,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Impact Biomedicines
|
| gptkbp:industry |
gptkb:drug
|
| gptkbp:key_people |
gptkb:Dr._John_D._Mc_Carty
|
| gptkbp:notable_products |
gptkb:Fedratinib
|
| gptkbp:website |
www.impactbiomedicines.com
|